IP Library Granted Patent US 11,279,934
Granted Patent B2
US 11,279,934 · App. 15/307,512 · Granted Mar 22, 2022

Methods for treating cancer using nucleic acids targeting MDM2 or MYCN

Inventors: Michael Byrne (Natick, MA); Karen G. Bulock (Mendon, MA); James Cardia (Franklin, MA)
Assignee: Phio Pharmaceuticals Corp.
C12N15/1135C12N15/113C12N2310/14C12N2310/315C12N2310/3515C12N2310/53C12N2320/32C12N2320/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,279,934
App. No.
15/307,512
Granted
Mar 22, 2022
Kind
B2
Abstract

Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.

Claims (10)

1. A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 2 homolog (MDM2),

wherein the nucleic acid molecule is an isolated double stranded nucleic acid molecule that comprises a sense strand and an antisense strand,

wherein the sense strand of the isolated double stranded nucleic acid molecule comprises SEQ ID NO: 727 (mC.mA.A.A.G.mA.A.G.mC.mU.A*mA*mA-Chl), and wherein the antisense strand of the isolated double stranded nucleic acid molecule comprises SEQ ID NO: 752 (P.mU.fU.fU.A.G.fC.fU.fU.fC.fU.fU.fU.G*fC*A*fC*A*fU*G).

2. The method of claim 1 , wherein the cancer is retinoblastoma, neuroblastoma, or glioblastoma.

3. The method of claim 1 , wherein the cancer is located in the eye.

4. The method of claim 3 , wherein the cancer is located in the retina.

5. The method of claim 1 , wherein the isolated double stranded nucleic acid molecule is in a composition formulated for topical delivery or is in a composition formulated for delivery to the eye.

6. The method of claim 5 , wherein the isolated double stranded nucleic acid molecule is in a composition formulated for intravitreal injection, subretinal injection, or subconjunctival administration.

7. The method of claim 1 , further comprising administering a second isolated double stranded nucleic acid molecule that is directed against a gene encoding a different protein, or that is directed against a gene encoding the same protein to the subject.

8. The method of claim 1 , wherein the isolated double stranded nucleic acid molecule is administered more than once.

Assignments (2)
CHANGE OF NAME Recorded Dec 7, 2018
From: RXI PHARMACEUTICALS CORPORATION
To: PHIO PHARMACEUTICALS CORP.
Reel/Frame 048380/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2017
From: BYRNE, MICHAEL; BULOCK, KAREN G.; CARDIA, JAMES
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 041694/0198 →
Continuity (2)
Provisional Application 61985446 · Apr 28, 2014
Related Publication 20170051288A1 · Feb 23, 2017
Cited By (2)
US 12,544,344 US 12,637,677